Mammary Cell News Volume 11.45 | Nov 21 2019

TOP STORY

Prolyl Hydroxylase Substrate Adenylosuccinate Lyase Is an Oncogenic Driver in Triple Negative Breast Cancer

Scientists identified adenylosuccinate lyase (ADSL) as an EglN2 hydroxylase substrate in triple negative breast cancer (TNBC). ADSL expression was higher in TNBC than other breast cancer subtypes or normal breast tissues. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Study of the Antitumor Effects and the Modulation of Immune Response by Histamine in Breast Cancer

Researchers assessed the therapeutic efficacy of histamine and histamine H4 receptor ligands in a triple-negative breast cancer model developed in immunocompetent hosts. Tumors of 4T1 triple-negative breast cancer cells were orthotopically established in BALB/c mice. [Br J Cancer] Abstract

Cell-Membrane Permeable Redox Phospholipid Polymers Induce Apoptosis in MDA-MB-231 Human Breast Cancer Cells

The authors induced apoptosis in MDA-MB-231 human breast cancer cells by adding a cell-membrane permeable redox phospholipid polymer that could alter the intracellular redox. They found that apoptosis and the deactivation of oxidative phosphorylation were induced in the MDA-MB-231 cells in the presence of the oxidized form of the redox polymer. [Biomacromolecules] Abstract

VGLL4 Interacts with STAT3 to Function as a Tumor Suppressor in Triple-Negative Breast Cancer

Investigators demonstrated that VGLL4 was expressed at low levels in both triple negative breast cancer (TNBC) specimens and cell lines and that VGLL4 expression was negatively correlated with Ki67 expression and tumor size in TNBC patients. [Exp Mol Med] Full Article

The Orphan Nuclear Receptor Estrogen-Related Receptor Beta (ERRβ) in Triple-Negative Breast Cancer

Transcription factor activity was measured using promoter-reporter luciferase assays in triple-negative breast cancer cell lines. Semi-automatic quantification of immunohistochemistry measured estrogen-related receptor beta protein expression on a 150-patient tissue microarray series. [Breast Cancer Res Treat] Abstract

Anti-Breast Cancer Activity of Resveratrol Encapsulated in Liposomes

Resveratrol (RES) was loaded into peptide and sucrose liposomes to enhance the physico-chemical properties of RES and exploit RES delivery mediated by liposomes to effectively treat breast cancer. RES loaded peptide and sucrose liposomes were stable, had a good RES encapsulation efficiency, and prolonged RES-release in vitro. [J Mater Chem B] Abstract

Mitochondrial Fission Regulator 2 (MTFR2) Promotes Growth, Migration, Invasion and Tumour Progression in Breast Cancer Cells

Mitochondrial fission regulator 2 (MTFR2) was upregulated in breast cancer tissues and was strongly associated with tumor characteristics. Moreover, Kaplan-Meier and Cox proportional hazards analyses indicated that high MTFR2 expression was related to poor overall survival. [Aging (Albany NY)] Full Article

Long Noncoding RNA LINC00899 Suppresses Breast Cancer Progression by Inhibiting miR-425

Scientists found that LINC00899 was downregulated in breast cancer tissues and cell lines. Kaplan-Meier analysis showed that elevated LINC00899 expression was closely associated with better relapse-free survival in breast cancer, including the basal, luminal A or luminal B breast cancer subtypes. [Aging (Albany NY)] Full Article

Layer-by-Layer Assembled PLGA Nanoparticles Carrying miR-34a Cargo Inhibit the Proliferation and Cell Cycle Progression of Triple-Negative Breast Cancer Cells

Triple-negative breast cancer cells internalized layer-by-layer assembled nanoparticles (LbL NPs) to a greater extent than polyplexes comprised of poly-L-lysine and miRNA, and confocal microscopy showed that LbL NPs delivered a substantial fraction of miR-34a cargo into the cytosol. [J Biomed Mater Res A] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

KISS1 in Breast Cancer Progression and Autophagy

Researchers discuss the role of KISS1 in regulating metastases, the link between KISS1 expression and the autophagy-related biology of cancer cells and the perspectives of using KISS1 as a potential diagnostic marker for cancer progression as well as a new anti-cancer therapeutics. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Phoenix Molecular Designs Initiates its Phase I/Ib Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

Phoenix Molecular Designs announced that it has dosed the first patient in its Phase I/Ib study of PMD-026, the company’s lead product candidate. PMD-026 is a proprietary first-in-class orally-available kinase inhibitor for the potential treatment of patients with metastatic breast cancer and triple-negative breast cancer. [Phoenix Molecular Designs (PR Newswire, Inc.)] Press Release

CHMP Recommends EU Approval of Roche’s Kadcyla for the Adjuvant Treatment of People with HER2-Positive Early Breast Cancer with Residual Invasive Disease after Neoadjuvant Treatment

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Kadcyla^® for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease. [Roche] Press Release

Myriad Genetics Announces Regulatory Approval of the BRACAnalysis^® Diagnostic System in Japan for Breast Cancer Patients

Myriad Genetics, Inc. announced that Japan’s Ministry of Health, Labour and Welfare has approved the BRACAnalysis^® Diagnostic System to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management. [Myriad Genetics, Inc.] Press Release

Science Funders Gamble on Grant Lotteries

Albert Einstein famously insisted that God does not play dice. But the Health Research Council of New Zealand does. The agency is one of a growing number of funders that award grants partly through random selection. [Nature News] Editorial

The Science Institutions Hiring Integrity Inspectors to Vet Their Papers

Some researchers have their manuscripts screened for errors before they go to journals. [Nature News] Editorial

Foreign Interference Fears Prompt Guidelines for Australian Universities

New guidelines will help Australian universities protect themselves against foreign interference, says the country’s government. The advice follows concerns that foreign groups or governments, such as the government of China, might be seeking to instigate campus activities that are against Australia’s interests. [Nature News] Editorial

NEW Noncoding RNAs: Mechanism, Function and Therapies
January 12-16, 2020
Whistler, British Columbia, Canada

Visit our events page to see a complete list of events in the community.

NEW Associate Faculty Member – Breast and Ovarian Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Studentship – Focal Adhesions in Metastatic Breast Cancer (German Cancer Research Center in the Helmholtz Association)

Bioscience Leader – In Vitro Pharmacology in Oncology (AstraZeneca)

Group Leader – Digital Cancer Prevention (German Cancer Research Center in the Helmholtz Association)

Junior Group Leader – Bioinformatics in Translational Cancer Research (Mildred Scheel Career Center)

Assistant Professor Tenure Track – Medical Genetics and BC Cancer (The University of British Columbia)

Senior Lab Manager – Cancer Research (Karolinska Institutet)

Senior/Research Associate – In Vivo Pharmacology for Oncology Research (Moderna)

Postdoctoral Fellow – Breast Cancer Stem Cells (Dalhousie University)

Research Scholar – Breast Cancer (Eastern Virginia Medical School)

Postdoctoral Scholar – Breast Cancer (The University of Kentucky)

Postdoctoral Researcher – Breast and Ovarian Cancer (Curtin University)

Postdoctoral Position – Cancer Biology (Memorial Sloan Kettering Cancer Center)

Postdoctoral Associate – Immune Responses (The Jackson Laboratory)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.